Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes’ Lightning Talk at the NVIDIA GTC AI ...

Recursion Pharmaceuticals is a TechBio company trying to apply artificial intelligence (AI) to the new drug-discovery process. The first placebo-controlled trial results from Recursion Pharmaceuticals ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

We'll know a little more about the biotech's prospects in a year and a half. The process of developing novel medicines is notoriously complicated, expensive, and long. Though you might think it's ...

FDA truncates drug approval process; Makary pushes for more OTC drugs; Inside the rocky ride for Recursion Pharmaceuticals.

This thesis makes the case for an investment in Recursion Pharmaceuticals operating as a TechBio which "industrializes" the process of drug discovery in contrast to a typical biotech. The difference ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Ark Invest added to three positions that are well below last year's highs.

The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...